Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer

PURPOSE: Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jang Ho, Kim, Eun Young, Park, Cheol-Kyu, Lee, Shin Yup, Lee, Min Ki, Yoon, Seong-Hoon, Lee, Jeong Eun, Lee, Sang Hoon, Kim, Seung Joon, Lee, Sung Yong, Lim, Jun Hyeok, Jang, Tae-Won, Jang, Seung Hun, Lee, Kye Young, Lee, Seung Hyeun, Yang, Sei Hoon, Park, Dong Won, Park, Chan Kwon, Kang, Hye Seon, Yeo, Chang Dong, Choi, Chang-Min, Lee, Jae Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873329/
https://www.ncbi.nlm.nih.gov/pubmed/36049499
http://dx.doi.org/10.4143/crt.2022.381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873329/
https://www.ncbi.nlm.nih.gov/pubmed/36049499
http://dx.doi.org/10.4143/crt.2022.381

Ejemplares similares